GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: BIOD
Buy $5

BIODEL INC. (NASDAQ: BIOD) rated to Buy with price target $5 by Roth Capital

Monday,  May 18, 2015  8:25 AM ET by Betsy O'Brien Harrison

Roth Capital rated BIODEL
INC. (NASDAQ: BIOD) to Buy with price target $5.

Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The Company develops product candidates by applying its formulation technologies to existing drugs in order to improve their therapeutic results. The Company?s initial development efforts are focused on peptide hormones. The Company?s advanced product candidate, VIAject, has been studied in two pivotal Phase III clinical trials for the treatment of patients with Type 1 and Type 2 diabetes. Earlier stage product candidates include VIAtab, a sublingual tablet formulation of insulin and two preclinical product candidates for the treatment of osteoporosis. The Company has developed all of its product candidates utilizing its VIAdel technology that allows the Company to study the interaction between peptide hormones and small molecules.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy